Ramin Salehirad, MD, PhD

Ramin Salehi-Rad, MD, PhD

Assistant Professor, Department of Medicine, Division of Pulmonary and Critical Care





Pulmonary & Critical Care Medicine, David Geffen School of Medicine, Los Angeles, CA, 2017


Internal Medicine, David Geffen School of Medicine, Los Angeles, CA, 2012


MD, David Geffen School of Medicine, Los Angeles, CA, 2011
PhD, University of California, Los Angeles, CA, 2009
BS, University of California, Los Angeles, CA, 2001


Internal Medicine, David Geffen School of Medicine, Los Angeles, CA, 2014

Board Certifications

Critical Care Medicine, American Board of Internal Medicine, 2017
Pulmonary Disease, American Board of Internal Medicine, 2016
Internal Medicine, American Board of Internal Medicine, 2014

Contact Information

Scientific Interests

Dr. Salehi-Rad is a physician scientist engaged in clinical and translational research in lung cancer. Dr. Salehi-Rad's research primarily focuses on improving our understanding of the tumor microenvironment and mechanisms through which tumors evade host immune responses. Additionally, Dr. Salehi-Rad's lab is actively exploring the development of novel gene-modified dendritic cell cancer vaccines as a strategy for overcoming resistance to immunotherapy. As a Pulmonologist, Dr. Salehi-Rad specializes in early detection of lung cancer.

Highlighted Publications

Salehi-Rad R, Li R, Tran LM, Lim RJ, Abascal J, Momcilovic M, Park SJ, Ong SL, Shabihkhani M, Huang ZL, Paul M, Shackelford DB, Krysan K, Liu B, Dubinett SM. Novel Kras-mutant murine models of nonsmall cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden. Cancer Immunol Immunother. 2021 Aug;70(8):2389-2400. doi: 10.1007/s00262-020-02837-9. Epub 2021 Jan 28. PMID: 33507343; PMCID: PMC8289771.

Li R*, Salehi-Rad R* (* Co-first author), Crosson W, Momcilovic M, Lim RJ, Ong SL, Huang ZL, Zhang T, Abascal J, Dumitras C, Jing Z, Park SJ, Krysan K, Shackelford DB, Tran LM, Liu B, Dubinett SM. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer. Cancer Res. 2021 Jun 15;81(12):3295-3308. doi: 10.1158/0008-5472.CAN 20-3564. Epub 2021 Apr 14. PMID: 33853830; PMCID: PMC8776246.

Salehi-Rad R, Lim RJ, Du Y, Tran LM, Li R, Ong SL, Ling Huang Z, Dumitras C, Zhang T, Park SJ, Crosson W, Kahangi B, Abascal J, Seet C, Oh M, Shabihkhani M, Paul M, Krysan K, Lisberg AE, Garon EB, Liu B, Dubinett SM. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity. J Immunother Cancer. 2023 Sep;11(9):e006896. doi: 10.1136/jitc-2023-006896. PMID: 37730274; PMCID: PMC10510892.

Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clin Cancer Res. 2017 Aug 15;23(16):4556-4568. doi: 10.1158/1078 0432.CCR 16-2821. Epub 2017 May 3. PMID: 28468947; PMCID: PMC5599263.

Yanagawa J, Tran LM, Salehi-Rad R, Lim RJ, Dumitras C, Fung E, Wallace WD, Prosper AE, Fishbein G, Shea C, Hong R, Kahangi B, Deng JJ, Gower AC, Liu B, Campbell JD, Mazzilli SA, Beane JE, Kadara H, Lenburg ME, Spira AE, Aberle DR, Krysan K, Dubinett SM. Single Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma. Cancer Res. 2023 Oct 2;83(19):3305-3319. doi: 10.1158/0008-5472.CAN-23-0128. PMID: 37477508; PMCID: PMC10544016.